HomeHealthObesity is a complex chronic disease

Obesity is a complex chronic disease

Written by Dr Conor Woods, Consultant Endocrinologist in Naas General and Tallaght University Hospitals

Introduction and definition
The myth of obesity as being merely a lifestyle choice is slowly being debunked. People suffering with the chronic disease obesity are not being listened to, or given the right support and access to proven treatments.

We need to rid all misconceptions regarding obesity. It is simply not a disease that anyone chooses, ever.

Overweight and obesity are defined as abnormal or excessive fat accumulation that presents a risk to health.1 This is an excellent definition although identifying ‘fat ….that poses a risk to health’ isn’t always easy! Athletes can be ‘heavy’ but may not have obesity. ‘Thin’ people can have metabolic dysfunction with fatty liver disease or Type 2 Diabetes Mellitus (T2DM) from unseen excess visceral adiposity. We use surrogate markers of excess weight such as Body Mass Index (BMI) to help identify people at risk of the complications of obesity. Measuring weight and BMI can be clinically useful if interpreted appropriately and within the correct clinical context.

The explosion of overweight and obesity has been staggering in recent decades. This epidemic has been seen across the world in both rich and poor economies. In Ireland, the numbers are sobering, with a majority (>65 per cent) of adults having excess weight or obesity.2

Pathophysiology
Many of the underlying pathways causing obesity have been described and although further detail is required, we already know a lot about the factors that contribute to a person’s weight.3 On a very simple level, obesity is a neurological condition. The centres that ultimately control our appetite, energy intake and weight are based in the brain, in areas such as the hypothalamus and the arcuate nucleus. These specialised centres within the subconscious brain are ‘meeting points’ of nerves with many variable inputs and outputs. These centres output signals to trigger weight maintenance or weight gain via different mechanisms including alterations in hunger and satiety hormones.

For the majority of us, once excess energy is consumed and stored as fat tissue, our brains make our body keep it. Akin to the areas that control breathing or temperatures these appetite centres cannot be controlled by thinking or conscious mental effort at all – one cannot breathe less or reduce high temperatures by thought or will power; similarly we cannot think to eat less or burn energy more. The brain centres will react accordingly and make compensations elsewhere to maintain weight or trigger weight regain.

Photo: Matt Love and Maura Murphy

Our genetic make-up plays a major role in our energy homeostasis and is crucial in how these energy/weight centres in our brains respond to and control weight. Genome wide association studies, which examine thousands and thousands of genes and thousands of subtle gene alterations, show that persons with excess weight have multiple genetic alterations across hundreds of genes leading to increased susceptibility to weight gain. Interestingly the inverse is also true with ‘thin’ people having less of these genetic alterations; proving that thin people are not more virtuous, but instead have a different genetic make-up.4,5

Rarely, specific single gene abnormalities lead to significant obesity; examples include leptin deficiency and the melanocortin receptor 4 (MCR4) mutations in the hypothalamus. These examples both lead to excess overeating and massive weight gain. Both are also amenable to specific drug therapy.6

Our genetic heritage has evolved slowly over thousands of years and we are essentially ‘hard wired’ to store excess energy as fat tissue. But genes change slowly and take hundreds of years to change – how has the epidemic of weight gain happened over recent decades? Whilst our genetic make-up hasn’t changed significantly in recent times, the same is not true of our environment.

The world we live in is very different compared to that of our ancestors! To our species’ great success we have engineered our world to such a degree that a majority of us will rarely if ever experience hunger.

Central heating, refrigeration, transport, elevators, air conditioning, sedentary work, supermarkets, the ‘western’ diet and advertising are just a few of the many environmental factors that impact on energy balance and our weight.

Like any other complex chronic disease there are many other factors involved in excess weight and obesity. These include psychological issues around food (comfort or binge eating), mental health and medications such as steroids. More recently the gut microbiome has become a focus of attention for research and how different types of gut bacteria influence weight and health.

Consequences
Obesity is proven to cause over 200 distinct health problems; from poor mental health, cancer, liver disease, T2DM, Obstructive Sleep Apnoea (OSA), cardiovascular disease and osteoarthritis. Persons with obesity (PwO) are at higher risk of acute illness such as infection. Increased risk of ventilation and higher risk of death was clearly seen in PwO that contracted Covid-19.7

Obesity is also a risk factor for OSA with increased neck circumference adiposity being a significant anatomical risk factor. Obesity is associated with other chronic diseases such as excess liver fat deposition.

There has been a significant sea change in the area of liver disease over the last 20 years or so. Whilst alcohol remains a huge problem in Ireland, liver cirrhosis because of non-alcoholic fatty liver disease is now becoming the commonest reason for liver failure.

The number of cancer cases caused by obesity is estimated to be 20 per cent.8 Obesity is strongly linked with endometrial, oesophageal, colorectal, postmenopausal breast, prostate, and kidney cancers. Obesity may contribute an even higher risk of cancer, to post-menopausal women and the increase in incidence of endometrial cancer is of particular concern with over half of cases attributable to obesity.

The full list of obesity related complications is extensive. Chronic inflammation, crosstalk between cells and surrounding adipocytes, obesity-induced hypoxia, shared genetic susceptibility, and the functional impact on immune cells are some postulated mechanisms for disease causation and progression.

Stigma
Society in general and the structures within society such as the health system, frequently judge those with excess weight and obesity in a negative fashion. This stigma is a very real and lived experience for those with this chronic disease. People suffering from the disease obesity, in my experience; work hard, sometimes harder than anyone else, try their best every day and care very much about how they look and how they are perceived in their community.

Despite both our government and the European Union recognising obesity as a disease, we still lack the necessary supports to help treat PwO.

Government policy needs to move on from just simple prevention, and also invest in obesity treatments especially weight loss surgery.

A small optimistic sign is the recent launch of the model of care programme for the management of overweight and obesity.9 This is a positive first step in transforming Irelands approach to obesity.

Despite the excellent and growing scientific body of evidence clearly showing the reasons why people gain weight and develop obesity – there is significant on-going stigma and resistance to investing in obesity treatments. It remains perhaps the biggest obstacle in the treatment of this disease both at government and societal levels.

Treatment
The good news is there are options to help patients treat obesity. Prevention is crucial and will hopefully be a key feature of government policy going forward. Prevention of a disease however, is not the same as treatment.

Significant urgent investment is needed. It is also important to emphasise the need to gain health rather than just focus on weight loss per se.

Broadly speaking there are conservative treatments such as dietary and lifestyle interventions and drug options. There are also more invasive treatments such as bariatric surgery.

The ‘eat less and move more’ model widely preached across media and health services works for only a minority of patients. I don’t advocate any particular diet or exercise regime, rather I encourage PwO to find what works best for them with emphasis always on gaining health.

If there is little or no success on one particular treatment plan then I advise to consider stopping and trying another. Supervised very low calorie diets with sustained significant weight loss over a 12-month period has been shown to revert T2DM in PwO.10

There are a number of medications available to help PwO, lose weight. Medical therapies include Glucagon Like Peptide–1 receptor agonists (GLP-1) such as liraglutide 3mg, bupropion-naltrexone and orlistat.

For full prescribing information please see www.medicines.ie or EMA website for product SmPCs.

As with various weight loss diets and lifestyle plans, we cannot predict who will respond to a drug and frequently a trial of four to six months is required. Unfortunately, in those that lose weight, cessation of drug therapy usually results in weight regain.

Looking to the future, rare gene receptor abnormalities such as MCR4 in the hypothalamus are attracting interest as potential drug targets. Other gut hormone molecules and combination of gut hormones are in the pipeline and show extremely promising weight loss results.

Weight-loss surgery is an excellent treatment option for PwO, especially in those with associated health problems such as fatty liver, OSA or T2DM. Bariatric surgery is generally recommended for those with a BMI greater than 40kgs/m2 or at a lower cut-off 35kgs/m2 if there are metabolic complications such as T2DM. There are essentially two types of surgery carried out; sleeve gastrectomy and gastric bypass.

Both are excellent in achieving significant weight loss and gaining health. Large international studies show the benefits of these procedures in extending life, reversing T2DM, reducing liver disease, reducing OSA, reducing heart disease among many other benefits.11-15

Surgery does not cure obesity, but should rather be thought of as an adjunct therapy that helps patients lose significant weight and gain physical function and health.

Conclusion and summary
Obesity is common; a majority of us are overweight. Obesity is caused by a mixture of genetics, biology, environment and other factors all leading to excess weight gain. Despite maximal personal effort – it is extremely difficult for an individual to eat less and move themselves more, toward a leaner body. We all need to work hard at reducing stigma associated with obesity. Please accept and believe the science – surgery for weight loss is proven and is excellent at improving health. Ireland needs increased weight loss surgery capacity.

The newer medications that are beginning to come on stream offer a very promising future for PwO. Looking forward, we need to plan for increased access to obesity treatment especially weight loss surgery. Government needs to be proactive and get the model of care funded and fully operational.

This article has been funded by Novo Nordisk. Novo Nordisk has not influenced the content of the article.

References

      1. Obesity and overweight. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight.
      2. Healthy Ireland Summary Report. Healthy Ireland Summary Report. https://assets.gov.ie/41141/e5d6fea3a59a4720b081893e11fe299e.pdf (2019).
      3. Upadhyay, J., Farr, O., Perakakis, N., Ghaly, W. & Mantzoros, C. ‘Obesity as a Disease’. Med. Clin. North Am. 102, 13–33 (2018).
      4. ‘Genetic architecture of human thinness compared to severe obesity’ – PubMed. https://pubmed.ncbi.nlm.nih.gov/30677029/.
      5. Clément, K. et al. ‘Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials’. Lancet. Diabetes Endocrinol. 8, 960–970 (2020).
      6. Kühnen, P. et al. ‘Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist’. N. Engl. J. Med. 375, 240–246 (2016).
      7. Simonnet, A. et al.’ High Prevalence of Obesity in Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Requiring Invasive Mechanical Ventilation’. Obesity 28, 1195–1199 (2020).
      8. De Pergola, G. & Silvestris, ‘F. Obesity as a major risk factor for cancer.’ J. Obes. 2013, (2013).
      9. ‘Model of Care for the Management of Overweight and Obesity’. https://www.hse.ie/eng/about/who/cspd/ncps/obesity/model-of-care/obesity-model-of-care.pdf.
      10. Lean, M. E. et al. ‘Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial’. Lancet (London, England) 391, 541–551 (2018).
      11. Sarabu, N. ‘Weight and Metabolic Outcomes 12 Years after Gastric Bypass’. N. Engl. J. Med. 378, 93–4 (2018).
      12. Syn, N. L. et al. ‘Association of metabolic-bariatric surgery with long-term survival in adults with and without diabetes: a one-stage meta-analysis of matched cohort and prospective controlled studies with 174 772 participants’. Lancet (London, England) 397, 1830–1841 (2021).
      13. La Sala, L. & Pontiroli, A. E. ‘Prevention of diabetes and cardiovascular disease in obesity’. Int. J. Mol. Sci. 21, 1–17 (2020).
      14. Uhe, I. et al. ‘Roux-en-Y gastric bypass, sleeve gastrectomy, or one-anastomosis gastric bypass? A systematic review and meta-analysis of randomized-controlled trials’. Obesity (Silver Spring). 30, 614–627 (2022).
      15. Quintas-Neves, M., Preto, J. & Drummond, M. ‘Assessment of bariatric surgery efficacy on Obstructive Sleep Apnea (OSA)’. Rev. Port. Pneumol. (English Ed. 22, 331–336 (2016).

Source link


Discover more from PressNewsAgency

Subscribe to get the latest posts sent to your email.

- Advertisment -